Sebastian Blaj1, Sebastian Nedelcut1, Max Mayr1, Hubert Leebmann1, Daniel Leucuta2, Gabriel Glockzin3, Pompiliu Piso4. 1. Department of General and Visceral Surgery, Krankenhaus Barmherzige Brüder, Prüfeninger Strasse 86, 93049, Regensburg, Germany. 2. Department of Informatics, University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania. 3. Department of Surgery, München Klinik Bogenhausen, Munich, Germany. 4. Department of General and Visceral Surgery, Krankenhaus Barmherzige Brüder, Prüfeninger Strasse 86, 93049, Regensburg, Germany. Pompiliu.piso@barmherzige-regensburg.de.
Abstract
PURPOSE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC. PATIENTS AND METHODS: In the present study, prospectively documented data of 474 consecutive patients treated with CRS and HIPEC between February 2011 and December 2015 in a high-volume certified reference center for peritoneal malignancies in Germany have been retrospectively analyzed. RESULTS: The re-operation rate was 14.5%. The most frequent reasons for revisional surgery were fascial dehiscence, intraabdominal hemorrhage, and anastomotic leak. Most complications occurred between postoperative day 7 and 9. However, postoperative bleeding was more common within the first 5 days after surgery. The overall in-hospital mortality rate was 2.1% for all patients and 10% after revisional surgery. CONCLUSIONS: CRS and HIPEC are associated with an acceptable re-operation rate and low mortality rate. Most frequently, re-operations are performed on 7-9 days after initial surgery due to fascial dehiscence, pancreatitis, or anastomotic leak. Postoperative bleedings are more common within the first 5 days after surgery.
PURPOSE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC. PATIENTS AND METHODS: In the present study, prospectively documented data of 474 consecutive patients treated with CRS and HIPEC between February 2011 and December 2015 in a high-volume certified reference center for peritoneal malignancies in Germany have been retrospectively analyzed. RESULTS: The re-operation rate was 14.5%. The most frequent reasons for revisional surgery were fascial dehiscence, intraabdominal hemorrhage, and anastomotic leak. Most complications occurred between postoperative day 7 and 9. However, postoperative bleeding was more common within the first 5 days after surgery. The overall in-hospital mortality rate was 2.1% for all patients and 10% after revisional surgery. CONCLUSIONS: CRS and HIPEC are associated with an acceptable re-operation rate and low mortality rate. Most frequently, re-operations are performed on 7-9 days after initial surgery due to fascial dehiscence, pancreatitis, or anastomotic leak. Postoperative bleedings are more common within the first 5 days after surgery.
Authors: William Jimenez; Armando Sardi; Carol Nieroda; Michelle Sittig; Vladimir Milovanov; Maria Nunez; Nail Aydin; Vadim Gushchin Journal: Ann Surg Oncol Date: 2014-07-02 Impact factor: 5.344
Authors: Mehraneh D Jafari; Wissam J Halabi; Michael J Stamos; Vinh Q Nguyen; Joseph C Carmichael; Steven D Mills; Alessio Pigazzi Journal: JAMA Surg Date: 2014-02 Impact factor: 14.766
Authors: Ingmar Königsrainer; Philipp Horvath; Florian Struller; Eva Maria Grischke; Diethelm Wallwiener; Alfred Königsrainer; Stefan Beckert Journal: Langenbecks Arch Surg Date: 2014-05-11 Impact factor: 3.445
Authors: Ingmar Königsrainer; Derek Zieker; Jörg Glatzle; Olivia Lauk; Julia Klimek; Stephan Symons; Björn Brücher; Stefan Beckert; Alfred Königsrainer Journal: World J Gastroenterol Date: 2012-05-07 Impact factor: 5.742
Authors: Lisa Überrück; Giorgi Nadiradze; Can Yurttas; Alfred Königsrainer; Ingmar Königsrainer; Philipp Horvath Journal: Ann Surg Oncol Date: 2020-11-09 Impact factor: 5.344